81. Stiff Man Syndrome This variant is sometimes called the Jerking Stiff Person syndromeor Progressive Encephalomyelitis with rigidity. Investigations. http://www.in-hln.org.uk/stiffman.htm

82. The Autoimmune Disease Sypport Organization 2 Septo Optic Dysplasia Sickle Cell Disease Sjogren syndrome Sjögren's syndrome 2 Sneddon syndrome Stiff-Man syndrome Stiff Person syndrome Sutton's Disease http://lvngwell.tripod.com/disease5.html

83. On Target - Weekly Journal, Issue January 13, 2002 HISTORY OF MEDICINE The Hospital Ship III. IMMUNOLOGY Stiff Person syndrome(SPS) IV. III. IMMUNOLOGY back to top. Stiff Person syndrome (SPS). http://www.targethealth.com/01132002.htm

(Complimentary Newsletter from Target Health Inc.) Home Qualifications On Target Staff ... Publications January 13, 2002 Contents: I. WHAT'S NEW American Society of Clinical Pharmacology and Therapeutics Annual Meeting II. HISTORY OF MEDICINE The Hospital Ship III. IMMUNOLOGY Stiff Person Syndrome (SPS) IV. GENETICS Oral Tumors V. WOMEN’S HEALTH A Fiber Diet and Heart Disease Risk VI. HEMATOLOGY Autoimmune Thrombocytopenic Purpura (AITP) VII. EPIDEMIOLOGY Gastroenteritis and Nursing Homes VIII. ONCOLOGY BRCA1 Gene in Ovarian Cancer IX. FDA New Guidance Document - Medical Device Software Validation TARGET HEALTH I. WHAT'S NEW back to top American Society of Clinical Pharmacology and Therapeutics Annual Meeting TARGET HEALTH is pleased to announce that our good friend and colleague Dr. Otto Mills (UMDNJ), will chair the Dermatology Session Symposium at the annual meeting of the ASCPT in Atlanta this March. Dr. Jonathan Wilkin (FDA) will also be presenting at the symposium, entitled Streamlining the Path to the Market. Dr. Mitchel’s presentation will address the use of Internet-based clinical trials. TARGET HEALTH will also be presenting a poster at the meeting.

84. ADVANCE For Audiologists | Daily News Watch An immunologic therapy administered to patients with stiff person syndrome (SPS)provides dramatic relief from disabling symptoms, according to a new study ( A http://www.advanceforaud.com/previousdnw/aadnw0121.html

Create username. Username Password help? HOME ARTICLES OF INTEREST BULLETIN BOARDS ... MAKE US YOUR HOME PAGE DAILY NEWS WATCH Updated Daily, Monday through Friday January 25, 2002 Immunotherapy Has Dramatic Results for Neurological Disorder An immunologic therapy administered to patients with stiff person syndrome (SPS) provides dramatic relief from disabling symptoms, according to a new study ("A Randomized Controlled Trial of High-Dose Intravenous Immunoglobulin in the Treatment of Patients with Stiff Person Syndrome," by M. Dalakas, M. Fujii, M Li, et al., New England Journal of Medicine , 345: 1870-1876). The therapy is intravenous immunoglobulin (IVIg). The success of the treatment supports the theory that SPS is the result of an autoimmune response gone awry in the brain and spinal cord, stated principal author Marinos C. Dalakas, MD, chief of the Neuromuscular Diseases Section of the National Institute of Neurological Disorders and Stroke (NINDS). SPS is characterized by fluctuating muscle rigidity in the trunk and limbs and a heightened sensitivity to stimuli such as noise, touch and emotional distress that can set off muscular spasms. People with SPS often are too disabled to walk or move or are afraid to leave their house because of stimuli-triggered spasms and frequent falls. Since the 1980s, researchers have known that people with SPS have elevated circulating antibodies against a particular enzyme, glutamic acid decarboxylase (GAD65). This enzyme is involved in the synthesis of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter that controls muscle movement. Since GABA modulates the action of the excitatory muscular neurotransmitters, lower levels of circulating GABA allow the excitatory neurotransmitters to hijack communications between the brain and the motor system, overstimulating the muscles into stiffness and spasm.

85. ScienceDaily News Release: Immunotherapy Treatment Shows Dramatic Results For Ra An immunologic therapy, intravenous immunoglobulin (IVIg), administered to patientssuffering from stiff person syndrome (SPS), provides dramatic relief from http://www.sciencedaily.com/releases/2001/12/011227074636.htm

Search Our Archives Keywords: Order by: date relevance More options Get ad-free access with email updates sign up or log in Text size: A A A Welcome Home page About this site Awards, reviews News Summaries Headlines Topics Shop Our stuff Browse books Magazines Software Contribute Register free Post release Edit profile Review hits Advertise Media kit Traffic stats Contact us Previous Story ... Related Stories Next Story Source: NIH/National Institute On Aging Date: Immunotherapy Treatment Shows Dramatic Results For Rare Neurological Disorder An immunologic therapy, intravenous immunoglobulin (IVIg), administered to patients suffering from stiff person syndrome (SPS), provides dramatic relief from disabling symptoms, according to a study appearing in the December 27, 2001, issue of The New England Journal of Medicine.* The study’s principal author, Marinos C. Dalakas, M.D., chief of the Neuromuscular Diseases Section of the National Institute of Neurological Disorders and Stroke, says that the success of the treatment supports the theory that SPS is the result of an autoimmune response gone awry in the brain and spinal cord. SPS is characterized by fluctuating muscle rigidity in the trunk and limbs and a heightened sensitivity to stimuli such as noise, touch, and emotional distress that can set off muscular spasms. People with SPS are often too disabled to walk or move, or are afraid to leave the house because of stimuli-triggered spasms and frequent falls. The incidence of SPS has been estimated at one in every one million persons, but according to Dr. Dalakas, “the disorder is so often misdiagnosed – as Parkinson’s disease, multiple sclerosis, fibromyalgia, psychosomatic illness, or anxiety and phobia – that its actual incidence is probably much higher.”

86. Médecine Interne Translate this page Commentaire au 26-05-00. Commentaires (Dr. P.Blanche) - Le syndrome de l'hommeraide (STIFF man syndrome ou mieux STIFF person syndrome ou encore mieux http://www.uvp5.univ-paris5.fr/UV_MED/MINT/STAF/Staff152.ASP

Staff de médecine interne Staff du : 26-05-00 Dr. Frédérique Aussert, Dr. Robin Dhote, Service de Médecine Interne (Pr. Christoforov), Cochin Patient de 71 ans, hospitalisé pour douleurs musculaires et articulaires avec altération de l'état général. Antécédents Hypertension artérielle. Coronaropathie. Dépression. Tabac. Histoire de la maladie - Mars Apparition brutale de douleurs musculaires : crampes de l'épaule droite avec impotence fonctionnelle partielle. Généralisation des symptômes aux membres inférieurs et au bras gauche. Perte de poids de 20 kgs en deux ans. FAN, FR, CPK, TSH normaux. Cliniquement ROT présents et symétriques - sensibilité normale. Force musculaire normale. Ténosynovite métacarpophalangienne de la main droite. Contractures musculaires généralisés et migratrices. Examens complémentaires Syndrome inflammatoire discret VS : 24, CRP à 25. Bilan hépatique, T4, TSH, aldolase, EPS, Ca Ph, LDH et CPK, C3C4, glycémie à jeûn normale. Anticorps anti-centromère et anti-nucléaires négatifs. Sérologies coxsakie, CMV, toxoplasmose, Lyme négatives.

87. Itb-candidate/selection Criteria Stroke, Cerebral Hemmorhage, Traumatic Brain Injury, Cerebral Palsy, AnoxicEncephalopathy, Stiff Person syndrome, Encephalitis, Near Drowning. http://www.southshoreneurologic.com/clinical/itb/itb-candidate.html

Candidates/Selection Criteria: STEP 1: Selection Criteria Spasticity is: Severe and interfering with care or function; causing complications. Patient is: Family is: motivated, committed, reliable, reasonable, cooperative. Goals are: explicit, collective, realistic, appropriate, mutually agreed upon. PATIENT SELECTION: Spinal Cord Disease Trauma or Slowly Progressive Problems: Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Stiff Person Syndome, Primary Lateral Sclerosis, Leukodystrophy, Familial Spastic Paraparesis, Spinal Cord Injury, Transverse Myelitis, Compressive Myelopathy, Spinal Cord Stroke Cerebral Spasticity: Stroke, Cerebral Hemmorhage, Traumatic Brain Injury, Cerebral Palsy, Anoxic Encephalopathy, Stiff Person Syndrome, Encephalitis, Near Drowning Dystonia with Spasticity Candidates/Selection Criteria STEP 2: Exclusion Criteria Infection or Pregnancy. History of allergy or hypersensitivity to baclofen Candidates/Selection Criteria STEP 3: General Clinical considerations: Critical issues to be considered: Unique features of ITB therapy are: graduated control of spasticity, upper extremity treatment, reversibility.

88. Katalog - Wirtualna Polska Serwis Katalog w Wirtualna Polska S.A. pierwszy portal w Polsce. http://katalog.wp.pl/DMOZ/Health/Conditions_and_Diseases/Neurological_Disorders/

Poczta Czat SMS Pomoc Szukaj.wp.pl: -Katalog -Polskie www -¦wiatowe www -Wirtualna Polska -FTP/Pliki -Grupy dyskusyjne -Encyklopedia -Produkty wp.pl Katalog Katalog ¦wiatowy DMOZ ... Neurological Disorders > Muscle Diseases Fakty o Katalogu Pomoc Regulamin Serwis szukaj ... Ostatnio dodane NAWIGACJA Fakty o katalogu Pomoc Regulamin Serwis Szukaj ... FAQ Dodaj stronê Katalog WP Polskie Strony WWW Oferta dla firm WP-HIT ... Wirtualna Polska

89. AWMF Online - Leitlinie Neurologie: Stiff Man-Syndrom (SMS; Synonym: Stiff Perso http://www.uni-duesseldorf.de/WWW/AWMF/ll/neur-080.htm

AWMF online A rbeitsgemeinschaft der W issenschaftlichen M edizinischen F achgesellschaften AWMF-Leitlinien-Register Nr. 030/080 Entwicklungsstufe: Stiff man-Syndrom (SMS; Synonym: Stiff person-Syndrom) Definition Klinik Erkrankungsalter 13 - 72 Jahre (Mittel 46 Jahre) Spontanverlauf und -prognose Fixierte Hyperlordose, Ankylosen, Subluxationen, Spontanfrakturen Angstattacken Gesteigerte Schreckreaktionen Autonome Dysregulation profuses Schwitzen, Tachykardie, Mydriasis, arterielle Hypertension, Tachypnoe, oft von Spasmen begleitet Assoziation mit Autoimmun-Endokrinopathien Typ 1 Diabetes mellitus, Autoimmun-Thyreoiditis, Immunhyperthyreose, B12-Hypovitaminose Fehldiagnose Konversionsneurose Komplikationen Lebensbedrohliche autonome Entgleisungen, insbesondere bei Medikamentenentzug (vor allem Benzodiazepine) Untersuchungen Notwendig SMS PERM). EMG Liquor Im Einzelfall erforderlich Differentialdiagnosen Tetanus, Strychnin-Intoxikation ( EMG: Verlust der reflektorischen Inhibition, z.B: Masseterreflex) erworbene Hyperekplexie (obligater Kopfretraktionsreflex) Intraspinale Prozesse axiale Dystonie klinisch und elektrophysiologisch fehlende Reflexanomalien, geringe emotionale Beeinflussbarkeit

90. Welcome To The Pain Management Center Ice packs cold packs. MRI. Pic shoulder tear. RSDS. St. John's Wort. Stiff-personsyndrome. The Active Release Technique - ART. Pain Mgmt. Center Links http://www.citihealth.com/layout.Cfm?HC=25&Body=CenterArticle

91. SpringerLink: Neurological Sciences - Abstract Volume 23 Issue 4 (2002) Pp 145-1 Antibodies to GAD (GADAb) were first recognised in a patient affected by stiff-personsyndrome; subsequently they were reported in a large number of cases http://link.springer.de/link/service/journals/10072/bibs/2023004/20230145.htm

Neurological Sciences ISSN: 1590-1874 (printed version) ISSN: 1590-3478 (electronic version) Table of Contents Abstract Volume 23 Issue 4 (2002) pp 145-151 DOI 10.1007/s100720200055 review : Glutamic acid decarboxylase autoantibodies and neurological disorders M. Vianello, B. Tavolato, B. Giometto Department of Neurology and Psychiatry Sciences, Second Clinic, University of Padua, Via Vendramini 7, I-35121 Padua, Italy Received: 16 May 2002 / Accepted in revised form: 10 July 2002 Abstract. Glutamic acid decarboxylase (GAD) is the enzyme that catalyses the production of GABA, a major neurotransmitter of the central nervous system. Antibodies to GAD (GAD-Ab) were first recognised in a patient affected by stiff-person syndrome; subsequently they were reported in a large number of cases with type 1 diabetes. Recently GADAb have been described in a number of patients affected by chronic cerebellar ataxia, drug-resistant epilepsy and myoclonus. These cases usually harbour other autoantibodies or are affected by organ-specific autoimmune diseases. The role of GAD-Ab is still unclear; the lack of experimental models makes it difficult to investigate their potential pathogenetic role. However two mechanisms have been suggested: the reduction by GAD-Ab of GABA synthesis in nerve terminals or the interference with exocytosis of GABA. Key words Article in PDF format (62 KB) Online publication: January 16, 2003

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 5     81-91 of 91    Back | 1  | 2  | 3  | 4  | 5